New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
08:15 EDTSIEGY, LIFE, BDX, ABT, RHHBY, ILMN, A, ENZ, LMNX, HOLX, AFFXEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Enzo Biochem (ENZ) announced today that U.S. District Judge Leonard P. Stark has established August 18th as the date for a patent claim construction hearing, also called a Markman hearing, involving Enzo Life Science’s U.S. Patents Nos. 6,992,180, 7,064,197, and 8,097,405. The hearing will be held in Delaware District Court. One or more of these patents is asserted against Abbott Labs (ABT), Affymetrix (AFFX), Agilent (A), Becton Dickinson (BDX), Gen-Probe, Hologic (HOLX), Illumina (ILMN), Life Technologies (LIFE), Luminex (LMNX), Roche (RHHBY), and Siemens (SIEGY), and their related entities. At such a hearing, the Judge will be asked to issue rulings regarding the language and interpretation of Enzo's patents at issue in the case. Markman hearings are considered a key event in a patent lawsuit. The upcoming Markman ruling will define the property rights for the technologies that Enzo has invented. Such rulings often drive and inform many aspects of the litigation.
News For ENZ;ABT;AFFX;A;BDX;HOLX;ILMN;LIFE;LMNX;RHHBY;SIEGY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
05:48 EDTBDXBecton Dickinson named 2015 large cap top pick at Piper Jaffray
Piper Jaffray raised its price target for Becton Dickinson (BDX) shares to $160 from $141 and called the stock its 2015 large cap top pick. Piper expects upside to management's CareFusion (CFN) merger earnings accretion guidance and sees potential gross margin benefit from falling oil prices. The firm keeps an Overweight rating on the stock. Shares of the medical technology company closed yesterday down $1.71 to $134.04.
December 16, 2014
08:47 EDTRHHBYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
05:46 EDTRHHBYRoche launches PCR molecular diagnostic system for point of care environment
Subscribe for More Information
December 15, 2014
05:24 EDTRHHBYExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 12, 2014
11:19 EDTABTAbbott board increases quarterly dividend to 24c from 22c
The board of Abbott increased the company's quarterly common dividend to 24c per share from 22c per share. The cash dividend is payable Feb. 13, 2015, to shareholders of record at the close of business on Jan. 15, 2015.
05:52 EDTRHHBYRoche announces retirement of Genentech research head
Subscribe for More Information
December 11, 2014
08:35 EDTHOLXOvaScience names Arthur Tzianabos as president
Subscribe for More Information
05:24 EDTABTAbbott IRIDICA now available in Europe
Subscribe for More Information
December 9, 2014
16:17 EDTENZEnzo Biochem reports Q1 EPS (8c), one estimate (8c)
Subscribe for More Information
12:22 EDTRHHBYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
07:44 EDTRHHBYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:52 EDTSIEGYSiemens CEO says won't spend aggressively on M&A, Reuters reports
Siemens CEO Joe Kaeser stated that the company will not spend its money too aggressively in M&A and instead focus on organic growth, fix underperforming units, and looks to increase R&D spending, reports Reuters, citing Kaeser. Reference Link
December 8, 2014
08:31 EDTBDXBecton Dickinson and CareFusion sets date for special meeting in proposed merger
Becton, Dickinson (BDX) and CareFusion (CFN) announced that CareFusion expects to hold a special meeting on January 21, 2015 for CareFusion stockholders to consider and vote upon the proposed merger of CareFusion and BD. As previously announced on October 5, 2014, BD and CareFusion entered into a definitive agreement pursuant to which BD would acquire CareFusion in a stock and cash transaction. CareFusion stockholder approval is a condition to the merger. In addition to CareFusion stockholder approval, the proposed acquisition remains subject to certain other conditions and approvals, including approval of the proposed acquisition by the European Commission under the European Union Merger Regulation. CareFusion has fixed the close of business on December 18, 2014 as the record date for the purpose of determining the stockholders who are entitled to notice of, and to vote at, the special meeting.
07:26 EDTAFFXLeerink to hold a tour
Subscribe for More Information
December 5, 2014
15:49 EDTBDXBecton Dickinson, Aethon announce collaboration
Subscribe for More Information
11:33 EDTRHHBYGenentech to present clinical data at ASH
Subscribe for More Information
10:44 EDTAOptions with increasing implied volatility
Subscribe for More Information
05:55 EDTBDXCDC data postiive for flu testing companies, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use